{"id":23411,"date":"2022-12-23T16:28:00","date_gmt":"2022-12-23T08:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23411"},"modified":"2025-01-27T16:32:45","modified_gmt":"2025-01-27T08:32:45","slug":"msd-and-kelun-biotech-ink-record-breaking-adc-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23411","title":{"rendered":"MSD and Kelun Biotech Ink Record-Breaking ADC Deal"},"content":{"rendered":"\n

Merck, Sharp & Dohme (MSD, NYSE: MRK<\/a>) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to seven of Kelun’s pipeline antibody drug conjugates (ADCs). The deal covers global territories outside mainland China, Hong Kong, and Macau, and involves the two companies working together on development.<\/p>\n\n\n\n

Deal Details and Financials<\/strong>
Kelun-Biotech will receive a lump sum of USD 175 million in a non-refundable upfront payment, along with up to USD 9.3 billion in milestone payments and net sales-based tiered royalties. The deal is contingent on approval by the United States Department of Commerce anti-monopoly review and Kelun\u2019s shareholders.<\/p>\n\n\n\n

Previous Deals and Pipeline Highlights<\/strong>
In May and July of this year, MSD invested a cumulative USD 2.3 billion to obtain global rights to Kelun-Biotech\u2019s ADCs SKB264 and SKB315. SKB264, a TROP2 ADC developed by Kelun subsidiary Klus Pharma Inc., has obtained approval for a Phase III clinical study in triple-negative breast cancer in China. SKB315, meanwhile, is a Claudin18.2 ADC undergoing Phase I clinical trials. This latest deal further solidifies the strategic partnership between MSD and Kelun-Biotech, positioning both companies to advance innovative ADC therapies globally.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,16,20,1832,2675,176,903],"class_list":["post-23411","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cancer","tag-finance","tag-kelun-biotech-biopharmaceutical","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"\nMSD and Kelun Biotech Ink Record-Breaking ADC Deal - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to seven of Kelun's pipeline antibody drug conjugates (ADCs). The deal covers global territories outside mainland China, Hong Kong, and Macau, and involves the two companies working together on development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23411\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD and Kelun Biotech Ink Record-Breaking ADC Deal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23411\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-23T08:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T08:32:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23411#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23411\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD and Kelun Biotech Ink Record-Breaking ADC Deal\",\"datePublished\":\"2022-12-23T08:28:00+00:00\",\"dateModified\":\"2025-01-27T08:32:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23411\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cancer\",\"Finance\",\"Kelun-Biotech Biopharmaceutical\",\"Merck Sharp & Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23411#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23411\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23411\",\"name\":\"MSD and Kelun Biotech Ink Record-Breaking ADC Deal - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-23T08:28:00+00:00\",\"dateModified\":\"2025-01-27T08:32:45+00:00\",\"description\":\"Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to seven of Kelun's pipeline antibody drug conjugates (ADCs). The deal covers global territories outside mainland China, Hong Kong, and Macau, and involves the two companies working together on development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23411#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23411\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23411#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD and Kelun Biotech Ink Record-Breaking ADC Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD and Kelun Biotech Ink Record-Breaking ADC Deal - Insight, China's Pharmaceutical Industry","description":"Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to seven of Kelun's pipeline antibody drug conjugates (ADCs). The deal covers global territories outside mainland China, Hong Kong, and Macau, and involves the two companies working together on development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23411","og_locale":"en_US","og_type":"article","og_title":"MSD and Kelun Biotech Ink Record-Breaking ADC Deal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23411","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-23T08:28:00+00:00","article_modified_time":"2025-01-27T08:32:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23411#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23411"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD and Kelun Biotech Ink Record-Breaking ADC Deal","datePublished":"2022-12-23T08:28:00+00:00","dateModified":"2025-01-27T08:32:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23411"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cancer","Finance","Kelun-Biotech Biopharmaceutical","Merck Sharp & Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23411#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23411","url":"https:\/\/flcube.com\/?p=23411","name":"MSD and Kelun Biotech Ink Record-Breaking ADC Deal - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-23T08:28:00+00:00","dateModified":"2025-01-27T08:32:45+00:00","description":"Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to seven of Kelun's pipeline antibody drug conjugates (ADCs). The deal covers global territories outside mainland China, Hong Kong, and Macau, and involves the two companies working together on development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23411#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23411"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23411#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD and Kelun Biotech Ink Record-Breaking ADC Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23411"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23411\/revisions"}],"predecessor-version":[{"id":23412,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23411\/revisions\/23412"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}